Study to Evaluate Broadlumab vs Placebo and Ustekinumab
Phase 3
Terminated
- Conditions
- Psoriasis
- Interventions
- Biological: 210mg BrodalumabBiological: 140mg BrodalumabBiological: UstekinumabBiological: Placebo
- First Posted Date
- 2016-06-01
- Last Posted Date
- 2016-06-01
- Lead Sponsor
- MedDerm Associates
- Target Recruit Count
- 15
- Registration Number
- NCT02786732
- Locations
- 🇺🇸
MedDerm Associates, San Diego, California, United States
Comparison Study of Topical Acne Regimens
Phase 4
Completed
- Conditions
- Acne
- First Posted Date
- 2009-06-04
- Last Posted Date
- 2014-06-24
- Lead Sponsor
- MedDerm Associates
- Target Recruit Count
- 128
- Registration Number
- NCT00913185
- Locations
- 🇺🇸
MedDerm Associates, San Diego, California, United States
© Copyright 2025. All Rights Reserved by MedPath